CompletedNCT05729373
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Researchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Huntsville and 82 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: March 8, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 434
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, Bulgaria, Estonia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05729373
- Official title
Show the full official title
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Recruitment & locations
CompletedHuntsville, United States · Phoenix, United States · Culver City, United States
62 more locations
- Oceanside, United States
- Redlands, United States
- Sherman, United States
- Sherman Oaks, United States
- Temecula, United States
- Torrance, United States
- Upland, United States
- Jacksonville, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Savannah, United States
- Chicago, United States
- Warrenville, United States
- Boston, United States
- Watertown, United States
- Saint Charles, United States
- Cherry Hill, United States
- Marlton, United States
- Brooklyn, United States
- Cedarhurst, United States
- Mount Kisco, United States
- New York, United States
- North Canton, United States
- Oklahoma City, United States
- Allentown, United States
- Austin, United States
- Dallas, United States
- Draper, United States
- Sofia, Bulgaria
- Pleven, Bulgaria
- Varna, Bulgaria
- Tallinn, Estonia
- Tartu, Estonia
- Kuopio, Finland
- Helsinki, Finland
- Oulu, Finland
- Tampere, Finland
- Chikugo-shi, Japan
- Fukuoka, Japan
- Kitakyushu-shi, Japan
- Kurume-shi, Japan
- Kure-shi, Japan
- Sapporo, Japan
- Naha, Japan
- Urasoe-shi, Japan
- Meguro-ku, Japan
- Setagaya-ku, Japan
- Bratislava, Slovakia
- Košice, Slovakia
- Rimavská Sobota, Slovakia
- Vranov nad Topľou, Slovakia
- Zlaté Moravce, Slovakia
- Alcorcón, Spain
- Langreo, Spain
- Barcelona, Spain
- Madrid, Spain
- Málaga, Spain
- Gothenburg, Sweden
- Lund, Sweden
- Malmö, Sweden
- Stockholm, Sweden
Questions about this study
What did researchers investigate?
Researchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-363856 and Placebo.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me